Status:
public
Videos: (
0
) Documents: (
0
) Comments: (
0
)
Group description
Group Videos
No videos have been added jet. You may join this group and add yours now.
Group Documents
No documents have been added jet. You may join this group and add yours now.
News
- Affinium Pharmaceuticals, Ltd., Announces First Patient Dosed with Oral AFN-1252 in a Phase 2 Clinical Trial for Acute ...
AUSTIN, TX and TORONTO, ON, Feb. 1, 2012 /PRNewswire/ - Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial ... - Health warning as salami recalled
SALAMI sold at Queensland farmers' markets has been recalled by health authorities because it has been found to contain high levels of bacteria. - Salami recalled over harmful bacteria concern
Queensland Health is warning against consuming a batch of salami made by smallgoods company Backa Australia, after samples were found with high levels of bacteria. The company based in Beenleigh, in Queensland, has begun a voluntary recall of its chabi salami products sold at farmers markets in Brisbane and the Gold Coast last weekend (14-15 [...] - Protalex, Inc. Announces Completion of Dosing Patients in 4th Cohort of Its Phase 1b Dose Escalation Study of PRTX-100 ...
SUMMIT, N.J. -- Protalex, Inc. , a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases today announced it has completed ... - The RARE List(TM) - You Must See it to Believe it!
7,000 Different Rare Diseases and Disorders Comprise 65 Page RARE List(TM), 95% of the Medical Conditions Included on RARE List(TM) Have No FDA Approved Treatments - Mexicali Cheese: FDA Sues to Shut Queens Factory
FDA officials filed a lawsuit against Mexicali Cheese to shut down until the plant complies with food safety regulations, citing that the factory had potentially deadly bacteria and had failed to correct repeated health violations. - Affinium initiates AFN-1252 Phase 2 trial in acute bacterial skin & skin structure infections
Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections. - Venus Remedies Enters Japan Market With Vancoplus
Venus Remedies Enters Japan Market With Vancoplus - Progress Made in Developing Community-Acquired MRSA Vaccine
By Maryn McKenna of Nature magazine Over the years, Robert Daum has learned to respect his adversary. [More] - Vaccine development: Man vs MRSA
For decades, Robert Daum has studied the havoc wreaked by methicillin-resistant Staphylococcus aureus . Now he thinks he can stop it for good.